Literature DB >> 20511346

Goal attainment scaling as a measure of treatment success after physiotherapy for chronic low back pain.

Anne F Mannion1, Filomena Caporaso, Natascha Pulkovski, Haiko Sprott.   

Abstract

OBJECTIVES: In some chronic conditions, patient-specific tools with individualized items have proved to be more sensitive outcome instruments than fixed-item tools; their use has not yet been investigated in chronic low back pain (cLBP).
METHODS: Eleven males and 21 females [mean age 44.0 (12.3) years] with cLBP, undergoing a spine-stabilization physiotherapy programme, completed the Roland Morris (RM) Disability Scale and a 0-10 pain scale pre- and post-therapy. Post-therapy, goal attainment scaling (GAS) scores were calculated regarding achievement of 2-6 priority GAS goals established pre-therapy; global outcome of therapy was assessed on a 5-point Likert scale.
RESULTS: Approximately one-fifth of the individualized goals were not covered by items of the RM. Of the 121 individualized goals, 41 (34%) were achieved at the expected level, 42 (35%) were exceeded and 38 (31%) were not reached. GAS scores correlated with change scores for pain (r = 0.61, P < 0.0001) and RM (r = 0.49, P = 0.006). Sixty-five per cent of the patients had a successful outcome according to GAS (i.e. a score >or=50); 55%, according to global outcome (therapy helped/helped a lot); 39%, according to the RM score change (score decrease >or=30%); and 44%, according to the pain score change (score decrease >or=30%).
CONCLUSIONS: GAS demonstrates the achievement of important goals undetected by fixed-item measures and is a valid and sensitive outcome measure for assessing the success of rehabilitation in patients with cLBP.

Entities:  

Mesh:

Year:  2010        PMID: 20511346     DOI: 10.1093/rheumatology/keq160

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  How well do observed functional limitations explain the variance in Roland Morris scores in patients with chronic non-specific low back pain undergoing physiotherapy?

Authors:  F Caporaso; N Pulkovski; H Sprott; A F Mannion
Journal:  Eur Spine J       Date:  2012-03-20       Impact factor: 3.134

2.  Reviewer's comment on "five-year outcome of surgical decompression of the lumbar spine without fusion" by Mannion AF, Denzler R, Dvorak J, Grob D (doi:10.1007/s00586-010-1535-2).

Authors:  Alison H McGregor
Journal:  Eur Spine J       Date:  2010-08-31       Impact factor: 3.134

3.  Health behavior change counseling in surgery for degenerative lumbar spinal stenosis. Part I: improvement in rehabilitation engagement and functional outcomes.

Authors:  Richard L Skolasky; Anica M Maggard; David Li; Lee H Riley; Stephen T Wegener
Journal:  Arch Phys Med Rehabil       Date:  2015-03-28       Impact factor: 3.966

4.  Content validity of Patient-Reported Outcomes Measurement Information System (PROMIS) items in the context of HIV clinical care.

Authors:  Todd C Edwards; Rob J Fredericksen; Heidi M Crane; Paul K Crane; Mari M Kitahata; William C Mathews; Kenneth H Mayer; Leo S Morales; Michael J Mugavero; Rosa Solorio; Frances M Yang; Donald L Patrick
Journal:  Qual Life Res       Date:  2015-08-06       Impact factor: 4.147

Review 5.  Goal attainment scaling for patients with low back pain in rehabilitation: A systematic review.

Authors:  Douglas Haladay; Laura Swisher; Dustin Hardwick
Journal:  Health Sci Rep       Date:  2021-09-22

6.  Goal Attainment Scaling in Outpatient Physical Therapy for Chronic Low Back Pain: Protocol for a Mixed Methods Study.

Authors:  Douglas Haladay; Rebecca Edgeworth Ditwiler; Aimee B Klein; Rebecca Miro; Matthew Lazinski; Laura Lee Swisher; Jason Beckstead; Jay Wolfson; Dustin Hardwick
Journal:  JMIR Res Protoc       Date:  2022-03-07

7.  Detection of clinically relevant pain relief in cats with degenerative joint disease associated pain.

Authors:  M E Gruen; E Griffith; A Thomson; W Simpson; B D X Lascelles
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.